by Maria Zannes | Oct 28, 2025 | Press Releases
Australian patent strengthens global patent portfolio SAN ANTONIO, TX — October 28, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company’s noninvasive test for lung...
by Maria Zannes | Oct 20, 2025 | Press Releases
Visit the CyPath® Lung team at Booth #2242 October 19-22 SAN ANTONIO, Texas – October 20, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced...
by Maria Zannes | Oct 16, 2025 | Press Releases
U.S. award protects AI-built platform and adds to growing international patent portfolio SAN ANTONIO, TX — October 16, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath®...
by Maria Zannes | Oct 15, 2025 | Press Releases
SAN ANTONIO, TX — October 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced...
by Maria Zannes | Oct 9, 2025 | Press Releases
SAN ANTONIO, Texas (October 9, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced definitive...
